Evans WE - Search Results

1

Methotrexate bioavailability after oral and intramuscular administration in children.

Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE. Teresi ME, et al. Among authors: evans we. J Pediatr. 1987 May;110(5):788-92. doi: 10.1016/s0022-3476(87)80025-2. J Pediatr. 1987. PMID: 3471936 Clinical Trial.

2

Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

Garré ML, Relling MV, Kalwinsky D, Dodge R, Crom WR, Abromowitch M, Pui CH, Evans WE. Garré ML, et al. Among authors: evans we. J Pediatr. 1987 Oct;111(4):606-12. doi: 10.1016/s0022-3476(87)80131-2. J Pediatr. 1987. PMID: 2958611

3

Enhanced hepatic drug clearance in patients with cystic fibrosis.

Kearns GL, Mallory GB Jr, Crom WR, Evans WE. Kearns GL, et al. Among authors: evans we. J Pediatr. 1990 Dec;117(6):972-9. doi: 10.1016/s0022-3476(05)80149-0. J Pediatr. 1990. PMID: 2246703

4

Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.

Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE. Christensen ML, et al. Among authors: evans we. J Clin Oncol. 1988 May;6(5):797-801. doi: 10.1200/JCO.1988.6.5.797. J Clin Oncol. 1988. PMID: 3163362

5

Pharmacokinetics of subcutaneous methotrexate.

Balis FM, Mirro J Jr, Reaman GH, Evans WE, McCully C, Doherty KM, Murphy RF, Jeffries S, Poplack DG. Balis FM, et al. Among authors: evans we. J Clin Oncol. 1988 Dec;6(12):1882-6. doi: 10.1200/JCO.1988.6.12.1882. J Clin Oncol. 1988. PMID: 3199171

6

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH. Evans WE, et al. N Engl J Med. 1986 Feb 20;314(8):471-7. doi: 10.1056/NEJM198602203140803. N Engl J Med. 1986. PMID: 3456079 Clinical Trial.

7

Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia.

Evans WE, Abromowitch M, Crom WR, Relling MV, Bowman WP, Pui CH, Ochs J, Dodge R. Evans WE, et al. NCI Monogr. 1987;(5):81-5. NCI Monogr. 1987. PMID: 3481040 Clinical Trial.

8

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance.

Crom WR, Glynn AM, Abromowitch M, Pui CH, Dodge R, Evans WE. Crom WR, et al. Among authors: evans we. Clin Pharmacol Ther. 1986 May;39(5):592-7. doi: 10.1038/clpt.1986.102. Clin Pharmacol Ther. 1986. PMID: 3516513 Clinical Trial.

9

Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia.

Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, Abromowitch M, Simone JV. Evans WE, et al. Lancet. 1984 Feb 18;1(8373):359-62. doi: 10.1016/s0140-6736(84)90411-2. Lancet. 1984. PMID: 6141424 Clinical Trial.

10

Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.

Evans WE, Hutson PR, Stewart CF, Cairnes DA, Bowman WP, Rivera G, Crom WR. Evans WE, et al. Clin Pharmacol Ther. 1983 Mar;33(3):301-7. doi: 10.1038/clpt.1983.37. Clin Pharmacol Ther. 1983. PMID: 6600662

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

629 results

Search Page